Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Non-Current Liabilities: 2020-2024

Historic Other Non-Current Liabilities for Apellis Pharmaceuticals (APLS) over the last 4 years, with Dec 2024 value amounting to $8.0 million.

  • Apellis Pharmaceuticals' Other Non-Current Liabilities fell 66.86% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 66.86%. This contributed to the annual value of $8.0 million for FY2024, which is 244.81% up from last year.
  • As of FY2024, Apellis Pharmaceuticals' Other Non-Current Liabilities stood at $8.0 million, which was up 244.81% from $2.3 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $345.2 million in FY2021 and a low of $2.3 million during FY2023.
  • For the 2-year period, Apellis Pharmaceuticals' Other Non-Current Liabilities averaged around $5.1 million, with its median value being $5.1 million (2023).
  • Data for Apellis Pharmaceuticals' Other Non-Current Liabilities shows a peak YoY surged of 244.81% (in 2024) over the last 5 years.
  • Over the past 4 years, Apellis Pharmaceuticals' Other Non-Current Liabilities (Yearly) stood at $253.6 million in 2020, then skyrocketed by 36.08% to $345.2 million in 2021, then reached $2.3 million in 2023, then spiked by 244.81% to $8.0 million in 2024.